CJC-1295 (No DAC) + Ipamorelin + GHRP-2 – 3mg / 3mg / 3mg (3ml Pen)

Combination research in the growth hormone secretagogue category rests on a single well-replicated observation: GHRH analogues and ghrelin receptor agonists act through separate receptor populations, and studies consistently report greater release when the two are investigated together than either produces alone. This preparation pairs a stabilised GHRH analogue with two ghrelin receptor agonists with differing selectivity profiles, which is the structural basis for that synergy.

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

Overlapping pathways

Both ghrelin agonists act at the same receptor, so their effects are not mechanistically distinct.

Selectivity profile

The combined profile reflects GHRP-2's intermediate cortisol and prolactin involvement.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.